Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Kyorin Pharmaceutical Co's Enterprise Value is 円75,457 Mil.
Kyorin Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円0 Mil. Therefore, Kyorin Pharmaceutical Co's EV-to-FCF for today is .
The historical rank and industry rank for Kyorin Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
TSE:4569'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 31.37
Current: 31.37
During the past 13 years, the highest EV-to-FCF of Kyorin Pharmaceutical Co was 31.37. The lowest was 0.00. And the median was 0.00.
TSE:4569's EV-to-FCF is ranked worse than 60.78% of 566
companies
in the Drug Manufacturers industry
Industry Median: 20.945
vs TSE:4569: 31.37
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kyorin Pharmaceutical Co (TSE:4569) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kyorin Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Kyorin Pharmaceutical Co's share price for today is 円1162.00.
Kyorin Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円60.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Kyorin Pharmaceutical Co EV-to-FCF Related Terms
Kyorin Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyorin Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Kyorin Pharmaceutical Co's EV-to-FCF falls into.
Kyorin Pharmaceutical Co's current Enterprise Value is 円75,457 Mil.
Kyorin Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Kyorin Pharmaceutical Co (TSE:4569) Overvalued in 2026?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円1,162.00 is trading 26.6% below its estimated GF Value™ of 円1,583.07.
GuruFocus considers Kyorin Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4569:
EV-to-FCF:
GF Value™: 円1,583.07 vs. price of 円1,162.00 (26.6% below fair value)
No single metric tells the full story. See the TSE:4569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
74GF Score
Get the complete analysis for TSE:4569
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4569 has been successfully added to your 
